Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.42 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350251 | 0.91 | GSK3B (0.53) | MEN1KMT2ANTSR1ABCG2RAB9A | |
| SCHEMBL5358394 | 0.88 | EGFR (0.56) | ABCG2EGFRGSK3BTTBK1TTBK2 | |
| SCHEMBL5348949 | 0.88 | ALK (0.52) | MEN1KMT2AABCG2RAB9AMAPT | |
| SCHEMBL14355886 | 0.87 | GSK3B (0.54) | MEN1KMT2AABCG2RAB9AMAPT | |
| SCHEMBL5348597 | 0.85 | TTBK1 (0.49) | MEN1KMT2ARAB9AEGFRRAF1 | |
| SCHEMBL5356576 | 0.81 | GSK3B (0.56) | ABCG2EGFRGSK3BTTBK1TTBK2 | |
| SCHEMBL5361357 | 0.80 | TTBK1 (0.48) | MEN1KMT2ARAB9AMAPTEGFR | |
| SCHEMBL5351369 | 0.79 | EGFR (0.59) | MEN1KMT2AABCG2RAB9AMAPT | |
| SCHEMBL5368887 | 0.76 | RAF1 (0.50) | MEN1KMT2AABCG2RAB9AMAPT | |
| SCHEMBL14355883 | 0.73 | RAB9A (0.48) | MEN1KMT2ARAB9AMAPTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | claimed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | claimed |
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | disclosed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | DPYD, COXFA4L2, MSH2 | MEN1 1175/4885KMT2A 3036/4885NTSR1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.